SCHEMBL5541867

SCHEMBL5541867

FC(F)(F)c1ccc(Cl)c(-c2[c]cco2)c1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM1A O60341 1/20 0.36
PDE2A O00408 5/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
ALDH1A1 P00352 1/20 0.35
HSD11B1 P28845 1/20 0.35
IL2 P60568 2/20 0.34
CTSS P25774 1/20 0.34
CTSK P43235 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
MCL1 Q07820 1/20 0.34
RORC P51449 1/20 0.33
RORB Q92753 1/20 0.33
TRPV1 Q8NER1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19785385 0.75 PDE2A (0.47) TSHRKDM1APDE2AMEN1KMT2A
SCHEMBL5534498 0.73 KIF11 (0.52) TSHRMEN1KMT2AALDH1A1
SCHEMBL28806082 0.73 KIF11 (0.52) TSHRSMN1; SMN2PDE2AMEN1KMT2A
SCHEMBL5537791 0.72 NOTUM (0.51) TSHRALDH1A1CTSS
SCHEMBL1477743 0.72 CYP2A6 (0.46) TSHRSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL5542849 0.71 KDM1A (0.37) TSHRSMN1; SMN2KDM1APDE2AMEN1
SCHEMBL4439285 0.71 PDE2A (0.39) TSHRKDM1APDE2AMEN1KMT2A
SCHEMBL3386023 0.71 FTO (0.37) TSHRSMN1; SMN2KDM1APDE2AMEN1
SCHEMBL3411258 0.69 KDM1A (0.38) TSHRKDM1APDE2AMEN1KMT2A
SCHEMBL5534450 0.69 KDM1A (0.36) TSHRKDM1APDE2AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 TSHR 319/4885SMN1; SMN2 3985/4885KDM1A 4622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.